modelS02AA30
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | AntiinfectivesCombinations | |
| ATC code: | S02AA30 | route: | topical |
| compartments: | 1 | |
| dosage: | 3 | mg |
| volume of distribution: | 10 | L |
| clearance: | 0.1 | L/h |
| other parameters in model implementation | ||
Antiinfectives, combinations (ATC code S02AA30) refer to ear preparations containing combinations of antibiotics for the treatment of infections of the ear, such as otitis externa or otitis media. These combinations may include antibiotics like neomycin, polymyxin B, or bacitracin, often used together for broader antimicrobial spectrum. Most of these combinations are topical and used primarily for local effect, and are approved for this indication.
Pharmacokinetics
Estimated pharmacokinetic parameters for typical topical otic antiinfective combinations in adults, as there are no published systemic PK data due to minimal systemic absorption after otic administration.
References
Aggarwal, R, et al., & Chauhan, MK (2020). Treatment and management strategies of onychomycosis. Journal de mycologie medicale 30(2) 100949–None. DOI:10.1016/j.mycmed.2020.100949 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32234349
Gupta, AK, & Studholme, C (2016). Novel investigational therapies for onychomycosis: an update. Expert opinion on investigational drugs 25(3) 297–305. DOI:10.1517/13543784.2016.1142529 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26765142
Pickert, A, & Raimer, S (2009). An evaluation of dapsone gel 5% in the treatment of acne vulgaris. Expert opinion on pharmacotherapy 10(9) 1515–1521. DOI:10.1517/14656560903002097 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19505219
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)